Építés alatt – nem éles oldal
Belépés
Fut, nem toboroz3. fázis

Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia

A legfontosabb adatok

Ki végzi
Neurocrine Biosciences
Hol
Ann Arbor, Atlanta, Aurora, Bethesda, Boston, Dallas, Great Neck, Indianapolis, Los Angeles, Minneapolis, New York, Philadelphia, Pittsburgh, Rochester, San Diego, San Francisco, Seattle, St Louis, Tulsa és Winston-Salem (Egyesült Államok)Mind a 20 helyszín megnézéseMég 17 másik országban, 42 helyszínen
Állapot
Fut, nem toboroz
Fázis
3. fázis
Résztvevők
182 fő vett részt
Kezdés
2020. dec. 16.
Várható befejezés
2027. aug.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
A vizsgált kezelések
  • Crinecerfont
  • Placebo
A regiszteradat frissítve
2026. május 11.

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 14 feltétel megnézéseKevesebb

Ki vehet részt

  • Be willing and able to adhere to the study procedures, including all requirements at the study center and return for the follow-up visit
  • Have a medically confirmed diagnosis of classic CAH due to 21-hydroxylase deficiency
  • Be on a stable steroid regimen
  • Participants of childbearing potential must agree to use an acceptable method of contraception during the study

Ki nem vehet részt

  • Have received any other investigational drug within 30 days before initial screening or plan to use an investigational drug (other than the study drug) during the study
  • Have current substance dependence, or current substance (drug) or alcohol abuse
  • Have had a blood loss ≥550 mL or donated blood or blood products within 8 weeks prior to the study
  • Have a history of bilateral adrenalectomy, hypopituitarism, or other condition requiring chronic glucocorticoid therapy
  • Have a clinically significant unstable medical condition or chronic disease other than CAH
  • Have a history of cancer unless considered cured
  • Have a known history of clinically significant arrhythmia or abnormalities on ECG
  • Have a known hypersensitivity to any corticotropin releasing hormone receptor antagonists
  • Have a diagnosis of any of the other known forms of classic CAH
  • Are pregnant

Helyszínek itt: Egyesült Államok

Még 17 másik országban, 42 helyszínen

  • Ann Arbor, MichiganHospital not named in the registry
  • Atlanta, GeorgiaHospital not named in the registry
  • Aurora, ColoradoHospital not named in the registry
  • Bethesda, MarylandHospital not named in the registry
  • Boston, MassachusettsHospital not named in the registry
  • Dallas, TexasHospital not named in the registry
  • Great Neck, New YorkHospital not named in the registry
  • Indianapolis, IndianaHospital not named in the registry
  • Los Angeles, CaliforniaHospital not named in the registry
  • Minneapolis, MinnesotaHospital not named in the registry
  • New YorkHospital not named in the registry
  • Philadelphia, PennsylvaniaHospital not named in the registry
  • Pittsburgh, PennsylvaniaHospital not named in the registry
  • Rochester, New YorkHospital not named in the registry
  • San Diego, CaliforniaHospital not named in the registry
  • San Francisco, CaliforniaHospital not named in the registry
  • Seattle, WashingtonHospital not named in the registry
  • St Louis, MissouriHospital not named in the registry
  • Tulsa, OklahomaHospital not named in the registry
  • Winston-Salem, North CarolinaHospital not named in the registry

A vizsgálatról

Mit akar kideríteni a vizsgálat

This is a Phase 3 study to evaluate the efficacy, safety, and tolerability of crinecerfont versus placebo administered for 24 weeks in approximately 165 adult participants with classic CAH due to 21-hydroxylase deficiency. The study consists of a 24-week randomized, double-blind, placebo-controlled period, followed by 1 year of active treatment with crinecerfont. Subsequently, participants may elect to participate in the open-label extension (OLE) period. The duration of participation in the study is approximately 20 months for the core study and will be a variable amount of time per participant for the OLE (estimated to be approximately 3 years).

A vizsgálat 2 csoportja

  • PlaceboPlacebo, összehasonlításként

    Placebo capsule, administered orally, twice daily for 24 weeks, followed by active treatment with crinecerfont for at least 1 year.

    Kezelés: Crinecerfont és Placebo

  • CrinecerfontA vizsgált kezelés

    Crinecerfont capsule, administered orally, twice daily for 24 weeks during the placebo-controlled treatment period, followed by active treatment with crinecerfont for at least 1 year.

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on és az EU hivatalos vizsgálati nyilvántartásában (CTIS).
Hivatalos cím
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Adult Subjects With Classic Congenital Adrenal Hyperplasia, Followed by Open-Label Treatment
Publikációk
A regiszteradat frissítve
2026. május 11.